NPS Preos Fracture Reduction, Bone Density Data To TOP Off Late-2004 NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NPS’ recombinant human parathyroid hormone Preos has shown a statistically significant 59% relative reduction in vertebral fracture risk in women with mild to moderate osteoporosis in the pivotal TOP study.
You may also be interested in...
NPS Postpones Preos Filing To Add Two-Year Data From PaTH Study
NPS postpones Preos NDA filing to add two-year data from PaTH study. Submission was originally slated for year-end 2004. Firm says two-year results have implications for use of the osteoporosis agent with Fosamax (alendronate)
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product